Literature DB >> 25329743

Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis-associated coagulopathy.

M Sivula1, J Hästbacka, A Kuitunen, R Lassila, T Tervahartiala, T Sorsa, V Pettilä.   

Abstract

BACKGROUND: Matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of metalloproteinases-1 (TIMP-1) have recently been suggested to be involved in coagulation process. Our objectives were to observe systemic MMP-8 and TIMP-1 levels in patients with severe sepsis with or without disseminated intravascular coagulation (DIC) and to study their relationship with coagulation markers over time.
METHODS: Our prospective pilot study included 22 patients with severe sepsis, nine (41%) of whom had overt DIC. We analysed MMP-8 and TIMP-1 serum concentrations by time-resolved immunofluorometric and enzyme-linked immunosorbent assays, respectively, on days 1, 2, 4 and 7 after the intensive care unit admission. Traditional coagulation tests were taken at the same time points. The results were compared between patients with and without DIC. Blood samples from 10 healthy volunteers were used to demonstrate normal levels.
RESULTS: Both patient groups had elevated levels of MMP-8 and TIMP-1 as compared with healthy controls. TIMP-1 concentration was almost twofold in DIC patients compared with those without DIC on the first 2 days. MMP-8 was elevated only on day 2. TIMP-1 correlated positively with the severity of coagulation disturbance and with disease severity scores. MMP-8 correlated negatively only with platelet count.
CONCLUSION: In this first human study, we could show that TIMP-1 is elevated in the early phase of sepsis-induced overt DIC, and it correlates both with degree of coagulopathy and disease severity. These findings suggest that TIMP-1 may play a role in the pathogenesis of DIC in septic patients.
© 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25329743     DOI: 10.1111/aas.12423

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  5 in total

1.  Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8.

Authors:  Delphine Demeestere; Eline Dejonckheere; Sophie Steeland; Paco Hulpiau; Jurgen Haustraete; Nick Devoogdt; Rielana Wichert; Christoph Becker-Pauly; Elien Van Wonterghem; Sylviane Dewaele; Griet Van Imschoot; Jeroen Aerts; Lutgarde Arckens; Yvan Saeys; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mol Ther       Date:  2016-01-18       Impact factor: 11.454

2.  TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: Multivariate model.

Authors:  Maria Eugenia Niño; Sergio Eduardo Serrano; Daniela Camila Niño; Diana Margarita McCosham; Maria Eugenia Cardenas; Vivian Poleth Villareal; Marcos Lopez; Antonio Pazin-Filho; Fabian Alberto Jaimes; Fernando Cunha; Richard Schulz; Diego Torres-Dueñas
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

Review 3.  Biomarkers of sepsis: time for a reappraisal.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Max Bisdorff; John C Marshall; Jean-Louis Vincent
Journal:  Crit Care       Date:  2020-06-05       Impact factor: 9.097

4.  MMP-9 Concentration in Peritoneal Fluid Is a Valuable Biomarker Associated with Endotoxemia in Equine Colic.

Authors:  Ann Kristin Barton; Ina-Gabriele Richter; Tanja Ahrens; Roswitha Merle; Abdollah Alalwani; Svenja Lilge; Katrin Purschke; Dirk Barnewitz; Heidrun Gehlen
Journal:  Mediators Inflamm       Date:  2021-01-05       Impact factor: 4.711

5.  The Effect of Thiamine, Ascorbic Acid, and the Combination of Them on the Levels of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) in Sepsis Patients.

Authors:  Bastian Lubis; Aznan Lelo; Putri Amelia; Agus Prima
Journal:  Infect Drug Resist       Date:  2022-09-30       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.